IRIS
CASADEI GARDINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.296
AS - Asia 6.150
NA - Nord America 5.959
SA - Sud America 1.482
Continente sconosciuto - Info sul continente non disponibili 498
AF - Africa 122
OC - Oceania 6
Totale 20.513
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.620
RU - Federazione Russa 3.614
SG - Singapore 2.168
CN - Cina 1.717
BR - Brasile 1.182
IT - Italia 895
HK - Hong Kong 677
VN - Vietnam 666
SE - Svezia 495
BD - Bangladesh 432
FR - Francia 299
RO - Romania 267
DE - Germania 201
CA - Canada 160
GB - Regno Unito 159
IN - India 132
AR - Argentina 125
MX - Messico 86
NL - Olanda 77
FI - Finlandia 56
ID - Indonesia 56
JP - Giappone 52
PL - Polonia 51
ZA - Sudafrica 50
AT - Austria 48
EC - Ecuador 48
CO - Colombia 37
ES - Italia 35
TR - Turchia 35
IQ - Iraq 34
VE - Venezuela 25
CL - Cile 21
MA - Marocco 21
MY - Malesia 19
LT - Lituania 18
PY - Paraguay 18
JM - Giamaica 16
AE - Emirati Arabi Uniti 15
PH - Filippine 15
CR - Costa Rica 14
IE - Irlanda 14
UA - Ucraina 14
UZ - Uzbekistan 14
NI - Nicaragua 13
PK - Pakistan 13
SA - Arabia Saudita 13
EG - Egitto 12
DZ - Algeria 11
AZ - Azerbaigian 10
HN - Honduras 10
IR - Iran 10
NP - Nepal 10
UY - Uruguay 9
TT - Trinidad e Tobago 8
BO - Bolivia 7
KE - Kenya 7
MD - Moldavia 7
PE - Perù 7
TW - Taiwan 7
AU - Australia 6
BE - Belgio 6
BH - Bahrain 6
CH - Svizzera 6
GT - Guatemala 6
IL - Israele 6
KZ - Kazakistan 6
OM - Oman 6
BA - Bosnia-Erzegovina 5
KR - Corea 5
SV - El Salvador 5
TN - Tunisia 5
AO - Angola 4
BB - Barbados 4
BG - Bulgaria 4
EU - Europa 4
KG - Kirghizistan 4
LB - Libano 4
PR - Porto Rico 4
TH - Thailandia 4
BM - Bermuda 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HR - Croazia 3
JO - Giordania 3
PA - Panama 3
PT - Portogallo 3
SI - Slovenia 3
A1 - Anonimo 2
AL - Albania 2
CG - Congo 2
CY - Cipro 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
KW - Kuwait 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
SR - Suriname 2
Totale 20.004
Salva come PNG Salva come JPEG
Città #
Dallas 1.555
Singapore 1.113
Moscow 767
Hong Kong 667
Ashburn 529
San Jose 469
New York 375
Beijing 329
Council Bluffs 322
Ho Chi Minh City 254
Shanghai 245
Lauterbourg 232
Hefei 220
Los Angeles 168
Milan 166
Lawrence 149
Princeton 149
Santa Clara 144
Hanoi 128
São Paulo 99
Rome 87
Orem 66
Boardman 56
Nuremberg 50
Montreal 47
Chicago 45
London 45
Naples 43
Warsaw 43
Tokyo 42
Rio de Janeiro 41
Helsinki 39
Brooklyn 37
Da Nang 35
Mexico City 35
Atlanta 34
Guangzhou 34
Munich 34
Belo Horizonte 32
Denver 32
Poplar 32
Stockholm 31
Toronto 31
Vienna 30
Houston 29
Buffalo 28
Chennai 27
Phoenix 27
Cesano Boscone 26
Porto Alegre 26
Frankfurt am Main 25
Johannesburg 25
Haiphong 24
Mumbai 23
Amsterdam 22
Biên Hòa 21
Manchester 21
Brasília 20
Guarulhos 20
Curitiba 19
Ankara 18
Shenzhen 18
Dhaka 17
Brescia 16
Lappeenranta 16
Quito 16
Seattle 16
Boston 15
New Delhi 15
San Francisco 15
Tianjin 15
Bari 14
Bologna 14
Philadelphia 14
Romagnano Sesia 14
Tashkent 14
Washington 14
Florence 13
Kingston 13
Turin 13
Baghdad 12
Catania 12
Changsha 12
Charlotte 12
Dublin 12
Figino 12
Guayaquil 12
Hải Dương 12
Managua 12
Miami 12
Newark 12
Querétaro 12
San José 12
Buenos Aires 11
Can Tho 11
Columbus 11
Kuala Lumpur 11
New Orleans 11
Omaha 11
Salvador 11
Totale 9.997
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 437
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments 425
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 422
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 351
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 158
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 156
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 147
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 141
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 140
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 135
Comparing Liver Venous Deprivation and Portal Vein Embolization for Perihilar Cholangiocarcinoma: Is It Time to Shift the Focus to Hepatic Functional Reserve Rather than Hypertrophy? 124
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 123
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 123
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 122
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 122
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 122
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 122
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents 122
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life 120
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 117
Combined hepatocellular-cholangiocarcinoma: morpho-molecular updates and considerations 117
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 116
Correction to: Prospective minimally invasive pancreatic resections from the IGOMIPS registry: a snapshot of daily practice in Italy on 1191 between 2019 and 2022 (Updates in Surgery, (2023), 75, 6, (1439-1456), 10.1007/s13304-023-01592-7) 116
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 116
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 115
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 115
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 115
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 114
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments 112
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 111
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 111
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients 107
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 105
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 105
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 104
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 103
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 103
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 103
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 103
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis 102
Retrospective Evaluation and Significance of Neutrophil-to-Lymphocyte Ratio Prior to and 1 month Following Microwave Ablation of Hepatocellular Carcinoma 101
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 101
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 99
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 99
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 98
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 97
Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review 97
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 95
Defining and predicting textbook outcomes for perihilar cholangiocarcinoma: analysis of factors improving achievement of desired postoperative outcomes 95
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 95
Correction: Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and 99mTc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization 90Y PET/CT 94
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming 94
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 94
Angiogenesis in biliary tract cancer: targeting and therapeutic potential 93
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 93
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 93
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 92
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 92
Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib 91
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 90
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 89
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 89
Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer (2016) 69 (110–118)] (S095980491632487X)(10.1016/j.ejca.2016.10.004) 89
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 89
EUS-GUIDED GASTROENTEROSTOMY FOR MANAGEMENT OF MALIGNANT GASTRIC OUTLET OBSTRUCTION: A PROSPECTIVE SERIES FROM THE PROTECT REGISTRY 88
Minimally Invasive Approach Provides Oncological Benefit in Patients with High Risk of Very Early Recurrence (VER) After Surgery for Intrahepatic Cholangiocarcinoma (iCCA) 88
Cholangiocarcinoma: new perspectives for new horizons 88
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 88
Mismatch repair deficiency as prognostic factor for stage III small bowel adenocarcinoma: A multicentric international study 87
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 87
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 87
A Clinicopathologic Comparison Between Early-Onset and Late-Onset Small Bowel Adenocarcinoma: A Multicenter International Study 86
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 85
The oncologic burden of residual disease in incidental gallbladder cancer: An elastic net regression model to profile high-risk features 85
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting 85
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 85
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 84
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 83
Sorafenib for the treatment of unresectable hepatocellular carcinoma: Preliminary toxicity and activity data in dogs 83
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma 82
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 82
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 82
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 82
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 81
BRAF-mutated colorectal cancer: Clinical and molecular insights 81
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 80
Over-the-Wire Lumen-Apposing Metal Stent Exchange for Management of a Long-Term Choledochoduodenostomy Dysfunction 79
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 78
Treatment options for advanced hepatocellular carcinoma: the potential of biologics 78
Platelets and hepatocellular cancer: Bridging the bench to the clinics 78
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 78
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 77
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 77
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 76
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 76
Same-session endoscopic diagnosis and symptom palliation in pancreato-biliary malignancies: Clinical impact of rapid on-site evaluation (ROSE) 75
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 74
Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials 74
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study 74
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 74
Totale 11.108
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.952
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.952
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022100 0 0 0 40 2 5 15 22 6 2 0 8
2022/2023842 325 171 70 12 2 123 25 46 49 5 6 8
2023/2024673 35 18 58 54 33 226 75 47 0 11 30 86
2024/20253.046 349 70 73 33 67 254 687 289 397 281 193 353
2025/202614.436 935 1.392 1.551 1.888 1.027 433 958 947 3.362 601 613 729
2026/20271.286 691 595 0 0 0 0 0 0 0 0 0 0
Totale 20.513